Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
231
datasets available to search
ShareScore release 0.9.0
Dataset results
231 results for “thrombolysis”
Standard vs. Ultrasound-assisted Catheter Thrombolysis for Submassive Pulmonary Embolism
ClinicalTrials.gov study NCT02758574. IPD Sharing: UNDECIDED. Countries: 1. Publications: 42.
Lyon Registry of Stroke Treated by Thrombolysis or Thrombectomy
ClinicalTrials.gov study NCT04620642. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Safety and efficacy of remote ischemic postconditioning after thrombolysis in patients with stroke
Open the record for dataset details and reuse information.
Data from: Intravenous thrombolysis in patients with chronic kidney disease: A systematic review and meta-analysis
<p><b><span>Objective</span></b><span> We sought to determine the association of chronic kidney disease (CKD) with the safety and efficacy of intravenous thrombolysis (IVT) among acute ischemic stroke (AIS) patients.</span></p> <p><b><span>Methods</span></b><span> Systematic review and pairwise meta-analysis of studies involving patients with CKD undergoing IVT for AIS were conducted to evaluate the following outcomes: symptomatic intracranial hemorrhage (sICH), asymptomatic and any ICH, in-hospital and 3-month mortality, </span>3-month favorable functional outcome (FFO, mRS 0-1) and <span>3-month functional independence (FI, mRS 0-2). CKD was defined using estimated glomerular filtration rate (eGFR) ranging from mild (eGFR: 60-89ml/min), moderate (eGFR: 30-59ml/min) and severe (eGFR: 15-29ml/min). </span></p> <p><b><span>Results</span></b><span> We identified 20 studies comprising </span>60,486 AIS <span>patients treated with IVT. In unadjusted analyses, CKD was associated with </span>sICH according to NINDS (7 studies; OR=1.41, 95%CI: 1.19–1.67) and ECASS-II (9 studies; OR=1.37, 95%CI: 1.01–1.85) definitions, any ICH (8 studies; OR=1.42, 95%CI: 1.18–1.70), 3-month mortality (9 studies; OR = 2.20, 95%CI: 1.72–2.81)<span>, </span>3-month FFO (8 studies; OR=0.58, 95%CI: 0.47–0.72) and <span>3-month FI</span> (8 studies; OR=0.57, 95%CI: 0.46–0.71). In adjusted analyses, <span>CKD</span> was associated with sICH according to NINDS (4 studies; OR<sub>adj</sub>=1.34, 95%CI: 1.01–1.79) and ECASS-II (3 studies; OR<sub>adj</sub>=2.08, 95%CI 1.27–3.43) definitions, any ICH (6 studies; OR<sub>adj</sub>=1.41, 95%CI 1.01–1.97), in-hospital mortality (2 studies; OR<sub>adj</sub> =1.19; 95%CI, 1.09-1.30) and 3-month FFO (6 studies; OR<sub>adj</sub>=0.80, 95%CI 0.70–0.92). </p> <p><b><span>Conclusions</span></b><span> After adjustment for confounders in this pairwise meta-analysis, moderate-severe CKD is associated with increased risks of intracranial hemorrhage and worse functional outcomes among AIS patients treated with IVT. </span></p>
Sex differences in IV thrombolysis treatment for stroke: a systematic review and meta-analysis
<p>Objective: A prior meta-analysis of reports published between 2000 and 2008 found that women were 30% less likely to receive IV rt-PA treatment for stroke than men; we updated this meta-analysis to determine if this sex difference still persisted.</p> <p>Methods: We identified studies that reported sex-specific IV rt-PA treatment rates for acute ischemic stroke published between 2008 and 2018. Eligible studies included representative populations of ischemic stroke patients from hospital-based, registry-based, or administrative data. Random effects odds ratios (OR) were generated to quantify sex differences.</p> <p>Results: Twenty-four eligible studies were identified during this 10-year period. The summary unadjusted OR based on 17 studies with data on all ischemic stroke patients was 0.87 (95% confidence interval [CI]=0.82-0.93), indicating that women had 13% lower odds of receiving IV rt-PA treatment than men. However, substantial between-study variability existed. Lower treatment odds in women were also observed in 7 studies that provided data on the subgroup of patients eligible for IV rt-PA treatment, although the summary OR of 0.95 (95% CI = 0.88-1.02) was not statistically significant. Examination of time trends across 33 studies published between 2000 and 2018 found evidence that the sex difference had narrowed in more recent years.</p> <p>Conclusions: Although there is considerable variability in the findings of individual studies, pooled data from recent studies shows that women with acute stroke are still less likely to be treated with IV thrombolysis compared with men. However, the size of this difference has narrowed compared to studies published before 2008.</p>
Data from: Outcomes of stroke patients treated with thrombolysis according to prestroke Rankin Scale scores
Background: It is common practice to withhold intravenous thrombolysis (IVT) for acute ischemic stroke in patients with preexisting disabilities. To test the hypothesis of an association of IVT and good clinical outcome also in patients with preexisting disabilities without an increase in mortality we analyzed data of 52,741 patients (15,317 treated with IVT) depending on prestroke Rankin Scale (pRS) score. Methods: We performed an observational study based on a consecutive stroke registry covering 10.8 million inhabitants. The outcome at discharge of stroke patients admitted in the time window of potential eligibility for IVT (<4.5h after stroke onset) was compared between patients treated and not treated with thrombolysis, stratified by pRS. Logistic regression analysis was used to estimate adjusted odds ratios (OR) along with 95% confidence intervals (CI) for favorable clinical outcome, defined as returning to the baseline pRS score or a score of 0 or 1 and mortality. Sensitivity analyses for subgroups of mildly and severely affected stroke patients were performed and influence of treatment duration was assessed. Results: Among included patients IVT rates were 32% for patients with pRS 0-1 and 20% for patients with pRS 2-5. IVT in patients with pRS of 0-4 was associated with a higher chance of returning to the baseline pRS (or a modified RS of 0/1), with ORs ranging between 1.42 (pRS 2; CI 1.16-1.73) and 1.73 (pRS 0; CI 1.61-1). The OR observed in patients with a pRS of 5 was 0.65 (CI 0.25-1.70). Observed associations remained consistent in sensitivity analyses. Subgroup analyses revealed no evidence of bias due to potential floor and ceiling effects. No evidence of elevated in-hospital mortality of patients treated with thrombolysis was observed. Conclusions: Our study suggests that IVT can be effective even in patients with severe preexisting disabilities, provided that they were not bedridden before stroke onset. Withholding IVT on the sole ground of prestroke disabilities may not be justified.
Adjunctive intraarterial thrombolysis in endovascular thrombectomy: a systematic review and meta-analysis
<p><b>Objective</b> To evaluate the safety and efficacy of intra-arterial thrombolysis (IAT) as an adjunct to endovascular thrombectomy (EVT) in ischemic stroke, we performed a systematic review and meta-analysis of the literature.</p> <p><b>Methods</b> Searches were performed using Medline, Embase, and Cochrane databases for studies that compared EVT to EVT with adjunctive IAT (EVT+IAT). Safety outcomes included symptomatic intracerebral hemorrhage (sICH) and mortality at three months. Efficacy outcomes included successful reperfusion (Thrombolysis in Cerebral Infarction score of 2b to 3), and functional independence, defined as a modified Rankin Scale score of 0 to 2 at three months.</p> <p><b>Results</b> Five studies were identified that compared combined EVT+IAT with alteplase <span><span>or urokinase to</span></span> EVT-only, and were included in the random effects meta-analysis. There were 1693 EVT patients, including 269 patients treated with combined EVT+IAT and 1424 patients receiving EVT-only. Pooled analysis did not demonstrate any differences between EVT+IAT and EVT-only in rates of sICH (OR: 0.61, 95% CI: 0.20-1.85; P=0.78), mortality (OR: 0.77, 95% CI: 0.54-1.10; P=0.15), or successful reperfusion (OR: 1.05, 95% CI: 0.52-2.15; P=0.89). There was a higher rate of functional independence in patients treated with EVT+IAT, although this was not statistically significant (OR: 1.34, 95% CI: 1.00-1.80; P=0.053).</p> <p><b>Conclusions</b> Adjunctive IAT appears to be safe. In specific situations, neurointerventionists may be justified in administering small doses of intraarterial alteplase or urokinase as rescue therapy during EVT.</p>
Stereotactic Operation Integrating With Thrombolysis in Basal Ganglion Hemorrhage Evacuation II
ClinicalTrials.gov study NCT04172376. IPD Sharing: Not stated. Countries: 0. Publications: 15.
Hospital Processes Reengineering of Intravenous Thrombolysis in Acute Ischemic Stroke in China
ClinicalTrials.gov study NCT02631317. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Thrombolysis in Myocardial Ischemia Trial (TIMI III)
ClinicalTrials.gov study NCT00000472. IPD Sharing: Not stated. Countries: 0. Publications: 18.
Comparison of Primary PCI vs. Post-thrombolysis PCI as Reperfusion Strategies in STEMI
ClinicalTrials.gov study NCT02268669. IPD Sharing: Not stated. Countries: 0. Publications: 3.
Intravenous Thrombolysis and NOAC
ClinicalTrials.gov study NCT06749834. IPD Sharing: NO. Countries: 1. Publications: 0.
Early Administration of Aspirin in Patients With Acute Ischemic Stroke Treated With Systemic Thrombolysis
ClinicalTrials.gov study NCT02921360. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Standard vs Ultrasound-assisted Catheter Thrombolysis for Submassive Pulmonary Embolism
ClinicalTrials.gov study NCT03086317. IPD Sharing: NO. Countries: 1. Publications: 0.
APRICOT-3: Antithrombotics in the Prevention of Reocclusion In COronary Thrombolysis -3
ClinicalTrials.gov study NCT00138034. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Normal Saline Infusion for Stroke After Intravenous Thrombolysis
ClinicalTrials.gov study NCT05993078. IPD Sharing: YES. Countries: 1. Publications: 0.
Evaluation Study of Early Administration of Evolocumab After Thrombolysis in Patients With Atherosclerotic Acute Ischemic Stroke
ClinicalTrials.gov study NCT07301372. IPD Sharing: NO. Countries: 1. Publications: 0.
Thrombolysis in Myocardial Infarction (TIMI)
ClinicalTrials.gov study NCT00000505. IPD Sharing: Not stated. Countries: 0. Publications: 60.
Sex differences in IV thrombolysis treatment for stroke: a systematic review and meta-analysis
Open the record for dataset details and reuse information.
Data from: Outcomes of stroke patients treated with thrombolysis according to prestroke Rankin Scale scores
Open the record for dataset details and reuse information.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.